Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00796133 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Dose-finding, Cross-over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women
A Phase 2 study of Ovulation, sponsored by Population Council.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 3
- Study locations
NCT00796133: Completed Phase 2 study of Ovulation, sponsored by Population Council.
NCT00796133 is a Phase 2 study of Ovulation that has completed, run by Population Council. The registered enrollment target is 18 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00796133, a Phase 2 study of Ovulation, has completed, sponsored by Population Council.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 2, dose-finding, cross-over study for the purposes of evaluating the effect of a NES/E2 transdermal gel delivery on ovulation suppression in normal ovulating women.
Conditions Studied
Interventions
- DRUG NES/E2 gel
Study Locations (3)
Other
- Instituto Chileno de Medicina Reproductiva - Santiago
- Profamilia - Santo Domingo
California
- Women's and Children's Hospital; LA County/USC Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2008-11 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
What the finished NCT00796133 record still lists
NCT00796133 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Ovulation appearing as the primary indexed condition, and to 1 intervention - of which NES/E2 gel is the first listed.
NCT00796133 reports a single indexed study location in Other, California.
Frequently Asked Questions
What is clinical trial NCT00796133 about?
NCT00796133 is a clinical study titled "A Phase 2, Dose-finding, Cross-over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women". This is a Phase 2, dose-finding, cross-over study for the purposes of evaluating the effect of a NES/E2 transdermal gel delivery on ovulation suppression in normal ovulating women.
What is the current status of trial NCT00796133?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2008-11. Estimated completion is 2014-01.
What conditions does trial NCT00796133 study?
This clinical trial studies the following conditions: Ovulation.
What interventions are being tested in trial NCT00796133?
The interventions under investigation include: NES/E2 gel (DRUG).
Who is sponsoring clinical trial NCT00796133?
This trial is sponsored by Population Council, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00796133 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovulation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00796133's enrollment target sits among peer trials
18 1898th of 2000 higher than 98 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia